DrugPatentWatch Database Preview
SANCUSO Drug Profile
» See Plans and Pricing
When do Sancuso patents expire, and what generic alternatives are available?
Sancuso is a drug marketed by Kyowa Kirin and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has forty patent family members in thirty-one countries.
The generic ingredient in SANCUSO is granisetron. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the granisetron profile page.
DrugPatentWatch® Generic Entry Outlook for Sancuso
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 22, 2025. This may change due to patent challenges or generic licensing.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for SANCUSO
| International Patents: | 40 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 36 |
| Clinical Trials: | 16 |
| Patent Applications: | 4,081 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SANCUSO |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SANCUSO |
| What excipients (inactive ingredients) are in SANCUSO? | SANCUSO excipients list |
| DailyMed Link: | SANCUSO at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for SANCUSO
Generic Entry Date for SANCUSO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FILM, EXTENDED RELEASE;TRANSDERMAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for SANCUSO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Fudan University | Phase 2 |
| Radboud University | Phase 4 |
| Milton S. Hershey Medical Center | Phase 2 |
Pharmacology for SANCUSO
| Drug Class | Serotonin-3 Receptor Antagonist |
| Mechanism of Action | Serotonin 3 Receptor Antagonists |
Paragraph IV (Patent) Challenges for SANCUSO
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| SANCUSO | FILM, EXTENDED RELEASE;TRANSDERMAL | granisetron | 022198 | 2015-10-09 |
US Patents and Regulatory Information for SANCUSO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kyowa Kirin | SANCUSO | granisetron | FILM, EXTENDED RELEASE;TRANSDERMAL | 022198-001 | Sep 12, 2008 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | Y | Get Started for $10 | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SANCUSO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Ukraine | 83362 | Get Started for $10 |
| South Africa | 200506128 | Get Started for $10 |
| China | 1747724 | Get Started for $10 |
| Israel | 169881 | Get Started for $10 |
| Austria | 368454 | Get Started for $10 |
| Russian Federation | 2355387 | Get Started for $10 |
| >Country | >Patent Number | >Estimated Expiration |
